Prognostic Impact of Oncogenic Fibroblast Growth Factor Receptor Alterations in Patients With Advanced Solid Tumors in a Real-World Setting.

Summary: Doctors investigated whether a specific genetic change, known as FGFR alterations, affects how long patients with advanced cancer live. By comparing over 1,000 patients—some with the genetic change and some without—who received standard treatments, they found no significant difference in survival times between the two groups. On average, patients in both groups lived for just over a year after starting treatment. This suggests that having this specific genetic alteration does not, by itself, predict a better or worse outcome for patients receiving standard care.